Type II Diabetes: The 45+ Market in the United States for Drugs and Diagnostics

 
   Single User - $2,995
   Corporate License - $5,990


Loading...
Published Jan 1, 2004 | 303 Pages | Pub ID: KLI910424

Type II diabetes is a metabolic disease the increases in incidence and prevalence with age. Type II diabetes (also known as "adult onset diabetes" and "non-insulin dependent diabetes") is a disease of glucose metabolism in which the individual becomes resistant to the glucose produced by the pancreas. As a result, glucose is not properly metabolized and serum glucose levels are increased, resulting in numerous complications vascular, renal, neurological and ophthalmological complications as the patient ages.

This volume of the Markets in Geriatric Medicine Series will look at the mechanisms involved in the pathology of both Type II diabetes, and the specific molecular processes that define this disease. The report will look at the technology and markets available for monitoring glucose levels, by patients, and the assays for hemoglobin A1C, ketones and microalbumin that are used to follow the progress of the disease and its complications.

It will also explore current treatment modalities for Type II diabetes, including oral hypoglycemics and insulin. It will describe new and emerging research and development efforts into the discovery of new therapeutic products that address this disease such as new oral hypoglycemic agents and both oral and inhaled dosage forms of insulin. We will investigate and discuss the latest in progress towards clinical development of biopharmaceuticals and cell-based therapeutics that may be introduced over the next decade for the treatment of Type II diabetes at its most basic level.

The report will look at the demographics of the aging United States population, the expected incidence and prevalence of Type II diabetes, and the United States markets for monitoring products and therapeutics, currently estimated at $4.5 billion and $5.5 billion, respectively, that are expected grow around these populations.

Chapter One: Executive Summary
  • Background
  • Scope and Methodology
  • Size and Growth of Market
  • Market Trends and Factors

Chapter Two: Introduction

  • Background
  • Population Demographics
  • Epidemiology and Pathology of Type II Diabetes

Chapter Three: Diabetes Monitoring

  • Background
  • Glucose Monitoring
  • Hemoglobin A1c
  • Ketone Monitoring
  • Microalbumin Monitoring

Chapter Four: Type II Diabetes Therapeutics

  • Current Approaches to Therapy
    • Patient Education
    • Exercise, Diet and Weight Control
    • Oral Hypoglycemic Agents
    • Insulin

    • Emerging Therapeutic Approaches
      • Prevention
      • Oral Hypoglycemic Agents
      • Insulin
      • Gene Therapy
      • Ă‚eta Cell Transplants

Chapter Five: Market Analysis

  • Market Size and Growth
    • Type II Diabetes Monitoring Markets
    • Insulin Therapy Markets
    • Oral Hypoglycemic Drugs

  • Competitive Outlook
    • Type II Diabetes Monitoring Markets
    • Insulin Therapy Markets
    • Oral Hypoglycemic Drug Markets

  • Market Trends

Chapter Six: Company Profiles

  • Overview
  • Abbott Laboratories
  • Alkermes, Inc.
  • Amylin Pharmaceuticals
  • Aventis Pharma U.S. Division of Aventis
  • The Bayer Group (USA) Subsidiary of Bayer AG
  • Bristol-Myers Squibb
  • Calyx Therapeutics
  • GlaxoSmithKline
  • Lexicon Genetics Corporation
  • Eli Lilly & Co.
  • Metabolex, Inc.
  • MitoKor
  • Novo Nordisk
  • Pfizer, Inc.
  • Takeda Pharmaceuticals North America
  • Telik, Inc.

Chapter Seven: Conclusions and Strategic Implications

  • First Conclusion
  • Second Conclusion
  • Third Conclusion
  • Fourth Conclusion
  • Fifth Conclusion
  • Sixth Conclusion
  • Seventh Conclusion
  • Eighth Conclusion
  • Ninth Conclusion
  • Tenth Conclusion
  • Eleventh Conclusion

APPENDIX: Company Directory

List of Exhibits
Chapter One: Executive Summary

  • Figure 1-1: Trending in United States Type II Diabetes Cases in the General Population and the 45+ Year Old Age Group: 2003 - 2013
  • Table 1-1: Estimated TAM Potential for the Age-Related Segments for Type II Diabetes Monitoring and Therapeutics Products in the U.S. Markets 2003-2013
  • Table 1-2: Estimated SAM Potential for the Age-Related Segments for Type II Diabetes Monitoring and Therapeutics Products in the U.S. Markets 2003-2013
  • Figure 1-2: Trending in the TAM and SAM Potential for Type II Diabetes Monitoring and Therapeutics Products in the United States in the Middle-Aged and Elderly Market Segments 2003-2013
  • Figure 1-3: Trending in the TAM and SAM Potential for Type II Diabetes Monitoring and Therapeutics Products in the United States in the 75+ Year-Old Market Segment 2003-2013
  • Figure 1-4: Trending in the TAM and SAM Potential for Type II Diabetes Monitoring and Therapeutics Products in the United States in the 65 to 74 Year-Old Market Segment 2003-2013
  • Figure 1-5: Trending in the TAM and SAM Potential for Type II Diabetes Monitoring and Therapeutics Products in the United States in the 45 to 54 Year-Old Market Segment 2003-2013
  • Figure 1-6: Trending in the TAM and SAM Potential for Type II Diabetes Monitoring and Therapeutics Products in the United States in the 55 to 64 Year-Old Market Segment: 2003 - 2013

Chapter Two: Introduction

  • Figure 2-1: Growth of the World’s Elderly (60+ Years) Population 2001-2025
  • Figure 2-2: Population Distribution of the United States by Age and Sex for 1999 and 2025
  • Figure 2-3: The Growing United States Population: 2003-2013
  • Figure 2-4: Increasing Median Age of the United States Population
  • Figure 2-5: Increasing Mean Age of the United States Population
  • Table 2-1: Aging U.S. Population by Age Group 2003-2013
  • Figure 2-6: Aging Trends in the United States Population for the Age Groups 45 Years and Older: 2003-2013
  • Figure 2-7: Changes in the Composition of the 45-Year-Old and Older Age Segment in the United States: 2003 and 2013
  • Table 2-2: Older Population Groups as Percentages of the Total United States Population by Age Group 2003-2013
  • Figure 2-8: Aging Trends by Percentage of the United States Population for the Age Groups 45 Years and Older: 2003-2013
  • Table 2-3: U.S. Prevalence of Type II Diabetes Cases (Diagnosed and Undiagnosed) by Total Population and Those 45 Years of Age and Older 2003-2013
  • Figure 2-9: Trending in United States Type II Diabetes Cases in the General Population and the 45+ Year Old Age Group: 2003 - 2013
  • Table 2-4: U.S. Prevalence of Type II Diabetes Cases (Total and Serviceable) by 45 Years of Age and Older Age Groups 2003-2013
  • Figure 2-10: Trending in United States Type II Diabetes Cases in the General Population and the 45+ Year Old Age Groups: 2003-2013

Chapter Three: Diabetes Monitoring

  • Table 3-1: Key Glucose Monitoring Products on the Market
  • Table 3-2: Key Ketone Monitoring Products on the Market

Chapter Four: Type II Diabetes Therapeutics

  • Table 4-1: Currently Marketed Oral Hypoglycemic Drugs for the Treatment of Type II Diabetes
  • Table 4-2: Comparison of Insulin Types
  • Table 4-3: Insulins Products on the U.S. Market
  • Table 4-4: Products in Development for the Treatment of Type II Diabetes

Chapter Five: Market Analysis

  • Table 5-1: The Total Projected United States Total Available Market (TAM) and Serviceable Available Market (SAM) for Diabetes (Type I and Type II) Monitoring and Therapeutic Products 2003-2013
  • Figure 5-1: Trending in the Total Projected U.S. Total Available Market (TAM) and Serviceable Available Market (SAM) for Diabetes (Type I and Type II) Monitoring and Therapeutic Products 2003-2013
  • Figure 5-2: Trending in the Total Projected U.S. Total Available Market (TAM) and Serviceable Available Market (SAM) for Diabetes (Type I and Type II) Monitoring Products 2003-2013
  • Figure 5-3: Trending in the Total Projected U.S. Total Available Market (TAM) and Serviceable Available Market (SAM) for Diabetes (Type I and Type II) Insulin Therapeutics 2003-2013
  • Figure 5-4: Trending in the Total Projected United States Total Available Market (TAM) and Serviceable Available Market (SAM) for Diabetes (Type I and Type II) Oral Hypoglycemic Therapeutics: 2003-2013
  • Table 5-2: The Total Projected United States Total Available Market (TAM) and Serviceable Available Market (SAM) for Type II Diabetes Monitoring and Therapeutic Products 2003-2013
  • Figure 5-5: Trending in the Total Projected United States Total Available Market (TAM) and Serviceable Available Market (SAM) for Type II Diabetes Monitoring and Therapeutic Products 2003-2013
  • Figure 5-6: Trending in the Total Projected United States Total Available Market (TAM) and Serviceable Available Market (SAM) for Type II Diabetes Monitoring Products 2003-2013
  • Figure 5-7: Trending in the Total Projected United States Total Available Market (TAM) and Serviceable Available Market (SAM) for Type II Diabetes Insulin Therapeutics 2003-2013
  • Figure 5-8: Trending in the Total Projected United States Total Available Market (TAM) and Serviceable Available Market (SAM) for Type II Diabetes Oral Hypoglycemic Therapeutics 2003-2013
  • Table 5-3: The Total Projected United States Total Available Market (TAM) and Serviceable Available Market (SAM) for Type II Diabetes Monitoring and Therapeutic Products in Individuals 45 Years of Age and Older 2003-2013
  • Figure 5-9: Trending in the Total Projected United States Total Available Market (TAM) and Serviceable Available Market (SAM) for Type II Diabetes Monitoring and Therapeutic Products in Patients 45 Years of Age and Older 2003-2013
  • Figure 5-10: Trending in the Total Projected United States Total Available Market (TAM) and Serviceable Available Market (SAM) for Type II Diabetes Monitoring Products in Patients 45 Years of Age and Older 2003-2013
  • Figure 5-11: Trending in the Total Projected United States Total Available Market (TAM) and Serviceable Available Market (SAM) for Type II Diabetes Insulin Therapeutics in Patients 45 Years of Age and Older 2003-2013
  • Figure 5-12: Trending in the Total Projected United States Total Available Market (TAM) and Serviceable Available Market (SAM) for Type II Diabetes Oral Hypoglycemic Therapeutics in Patients 45 Years of Age and Older 2003-2013
  • Table 5-4: United States Total and Serviceable Available Market Potential for Monitoring and Therapeutic Products in the 45+ Age Type II Diabetes Populations by Age Group: 2003 - 2013
  • Figure 5-13: Trending and Composition of the Total Available Market for Type II Diabetes Monitoring and Therapeutics in the United States Among Type II Diabetes Patients 45 Years of Age and Older by Product Group 2003-2013
  • Figure 5-14: Trending and Composition of the Serviceable Available Market for Type II Diabetes Monitoring and Therapeutics in the United States Among Type II Diabetes Patients 45 Years of Age and Older by Product Group 2003-2013
  • Figure 5-15: Trending and Composition of the Total Available Market for Type II Diabetes Monitoring and Therapeutics in the United States Among Type II Diabetes Patients 45 to 54 Years of Age by Product Group 2003-2013
  • Figure 5-16: Trending and Composition of the Serviceable Available Market for Type II Diabetes Monitoring and Therapeutics in the United States Among Type II Diabetes Patients 45 to 54 Years of Age by Product Group 2003-2013
  • Figure 5-17: Trending and Composition of the Total Available Market for Type II Diabetes Monitoring and Therapeutics in the United States Among Type II Diabetes Patients 55 to 64 Years of Age by Product Group 2003-2013
  • Figure 5-18: Trending and Composition of the Serviceable Available Market for Type II Diabetes Monitoring and Therapeutics in the United States Among Type II Diabetes Patients 55 to 64 Years of Age by Product Group 2003-2013
  • Figure 5-19: Trending and Composition of the Total Available Market for Type II Diabetes Monitoring and Therapeutics in the United States Among Type II Diabetes Patients 65 to 74 Years of Age by Product Group 2003-2013
  • Figure 5-20: Trending and Composition of the Serviceable Available Market for Type II Diabetes Monitoring and Therapeutics in the United States Among Type II Diabetes Patients 65 to 74 Years of Age by Product Group 2003-2013
  • Figure 5-21: Trending and Composition of the Total Available Market for Type II Diabetes Monitoring and Therapeutics in the United States Among Type II Diabetes Patients 75+ Years of Age by Product Group 2003-2013
  • Figure 5-22: Trending and Composition of the Serviceable Available Market for Type II Diabetes Monitoring and Therapeutics in the United States Among Type II Diabetes Patients 75+ Years of Age by Product Group 2003-2013
  • Table 5-5: United States Total and Serviceable Available Market Potential for Blood Monitoring Products in the 45+ Age Type II Diabetes Populations 2003 - 2013
  • Table 5-6: United States Total and Serviceable Available Market Potential for Insulin Products in the 45+ Age Type II Diabetes Populations 2003-2013
  • Table 5-7: United States Total and Serviceable Available Market Potential for Oral Hypoglycemic Agents in the 45+ Age Type II Diabetes Populations by Age Group 2003-2013